Monolithic Tofacitinib Tablet with pH-Independent Gelling Polymer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral formulations of tofacitinib, such as XELJANZ XR®, face challenges in manufacturing efficiency and bioequivalence, with osmotic pump systems being costly and previous modifications leading to incomplete drug dissolution due to slow hydration and pH-dependent solubility issues.
Innovation Solution
A monolithic tablet design utilizing a swellable hydrophilic matrix core with a water-soluble, pH-independent gelling control release polymer in both the core and coating, achieving a controlled release profile similar to osmotic pumps without the need for pore formers and maintaining solute concentration gradients for consistent drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If osmotic pump technology is used for controlled release, then pharmacokinetic profiles are improved, but manufacturing cost and complexity increase significantly
Solution Approach 1:
The patent removes the complex osmotic pump mechanism (drilled holes, semi-permeable coatings) and extracts only the essential function of controlled release, achieving it through a simpler monolithic matrix system with pH-independent gelling polymers
Solution Approach 2:
The invention replaces expensive, complex osmotic pump technology with a simpler, more cost-effective monolithic tablet formulation that achieves comparable controlled release performance without requiring sophisticated manufacturing equipment
2Reliability
If non-erodible materials with pore formers are used, then controlled release is achieved, but water penetration and hydration rates become slow
Solution Approach 1:
The patent changes the key parameter of polymer pH-dependency, using pH-independent gelling polymers that maintain consistent gel structure and drug release characteristics across different gastrointestinal pH conditions, improving both hydration rate and controlled release reliability
3Reliability
If alkalizing agents are added to reduce API solubility at low pH, then pH-dependent release is reduced, but drug release at high pH is limited
Solution Approach 1:
The patent eliminates the need for alkalizing agents entirely by using pH-independent gelling polymers, achieving complete drug release at high pH without the limitations imposed by solubility-reducing additives, thereby ensuring full bioavailability
4Ease of manufacture
If monolithic tablet design is used, then manufacturing is simplified, but water penetration and drug dissolution may be incomplete
Solution Approach 1:
The patent modifies the polymer characteristics by selecting pH-independent gelling polymers with appropriate viscosity grades (50-150 cP), which optimize water penetration and gel formation in the monolithic structure, ensuring complete drug dissolution while maintaining manufacturing simplicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The monolithic tablet provides a bioequivalent and cost-effective controlled release of tofacitinib, ensuring at least 60% drug release within 4 hours and 80% within 6 hours, overcoming the limitations of previous formulations in terms of manufacturing complexity and drug solubility.
Implementation Method 1
A monolithic tablet design utilizing a swellable hydrophilic matrix core
Implementation Method 2
a water-soluble, pH-independent gelling control release polymer
Implementation Method 3
maintaining solute concentration gradients for consistent drug delivery
Data Source
AI summary
The present invention relates to a monolithic tablet composition for oral administration of tofacitinib, or a pharmaceutically acceptable salt thereof.